SCHEMBL30733405

SCHEMBL30733405

Cc1cc(S(=O)(=O)N2CC3(CCCC3)c3ccccc32)ccc1F

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.50
HTT P42858 3/20 0.50
LMNA P02545 2/20 0.50
MAPK1 P28482 2/20 0.50
NPSR1 Q6W5P4 1/20 0.47
KMT2A Q03164 5/20 0.45
MEN1 O00255 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 4/20 0.43
POLB P06746 2/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
ACLY P53396 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
HSD17B10 Q99714 1/20 0.41
NOTUM Q6P988 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30733408 0.91 KMT2A (0.43) TSHRHTTLMNAMAPK1NPSR1
SCHEMBL30733423 0.83 KCNN4 (0.47) HTTLMNANPSR1KMT2ASMN1; SMN2
SCHEMBL25281852 0.82 MEN1 (0.54) LMNAKMT2AMEN1ALDH1A1GAA
SCHEMBL29386556 0.82 MEN1 (0.54) LMNAKMT2AMEN1ALDH1A1GAA
SCHEMBL30733401 0.80 NOTUM (0.45) ACLYNOTUM
SCHEMBL25276068 0.80 KMT2A (0.43) TSHRLMNAMAPK1NPSR1KMT2A
SCHEMBL26969760 0.78 ACLY (0.38) TSHRLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL26969734 0.78 MMP2 (0.44) HTTKMT2AMEN1ALDH1A1ACLY
SCHEMBL26969764 0.77 ACLY (0.41) KMT2AMEN1ALDH1A1ACLYNOTUM
SCHEMBL25238614 0.77 NOTUM (0.42) LMNAMAPTPOLBALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416262-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416262-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 TSHR 2030/4885HTT 1696/4885LMNA 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.